Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 4
2016 9
2017 5
2018 6
2019 2
2020 4
2021 11
2022 13
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642. Blood. 2022. PMID: 35609174 Free PMC article.
Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, Barraco F, Sève P, Jamilloux Y, Sujobert P. Bourbon E, et al. Among authors: heiblig m. Blood. 2021 Jul 1;137(26):3682-3684. doi: 10.1182/blood.2020010177. Blood. 2021. PMID: 33619558 Free article. Review. No abstract available.
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE. Sabatier M, et al. Among authors: heiblig m. Cancer Discov. 2023 Jul 7;13(7):1720-1747. doi: 10.1158/2159-8290.CD-22-0411. Cancer Discov. 2023. PMID: 37012202
Acute Promyelocytic Leukemia.
Thomas X, Heiblig M. Thomas X, et al. Among authors: heiblig m. Cancers (Basel). 2020 Dec 11;12(12):3718. doi: 10.3390/cancers12123718. Cancers (Basel). 2020. PMID: 33322368 Free PMC article.
VEXAS: where do we stand 2 years later?
Sujobert P, Heiblig M, Jamilloux Y. Sujobert P, et al. Among authors: heiblig m. Curr Opin Hematol. 2023 Mar 1;30(2):64-69. doi: 10.1097/MOH.0000000000000750. Epub 2022 Dec 30. Curr Opin Hematol. 2023. PMID: 36728604 Review.
From vacuoles to VEXAS.
Heiblig M, Sujobert P. Heiblig M, et al. Rheumatology (Oxford). 2023 Dec 1;62(12):3780-3781. doi: 10.1093/rheumatology/kead392. Rheumatology (Oxford). 2023. PMID: 37522863 No abstract available.
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
Polivka L, Madrange M, Bulai-Livideanu C, Barete S, Ballul T, Neuraz A, Greco C, Agopian J, Brenet F, Dubreuil P, Burdet C, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Gourguechon C, Damaj G, Frenzel L, Meni C, Bouktit H, Collange AF, Gaudy-Marqueste C, Gousseff M, Le Mouel E, Hamidou M, Neel A, Ranta D, Jaussaud R, Guilpain P, Canioni D, Molina TJ, Bruneau J, Lhermitte L, Garcelon N, Javier RM, Pelletier F, Castelain F, Retornaz F, Cabrera Q, Zunic P, Gourin MP, Wierzbicka-Hainaut E, Viallard JF, Lavigne C, Hoarau C, Durieu I, Heiblig M, Dimicoli-Salazar S, Torregrosa-Diaz JM, Soria A, Arock M, Lortholary O, Bodemer C, Hermine O, Rossignol J; CEREMAST network. Polivka L, et al. Among authors: heiblig m. J Allergy Clin Immunol. 2024 Jan;153(1):349-353.e4. doi: 10.1016/j.jaci.2023.08.015. Epub 2023 Aug 24. J Allergy Clin Immunol. 2024. PMID: 37633651 Free article.
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, Riescher Tuczkiewicz S, Henneton P, Guilpain P, Schleinitz N, Le Guenno G, Lobbes H, Lacombe V, Ardois S, Lazaro E, Langlois V, Outh R, Vinit J, Martellosio JP, Decker P, Moulinet T, Dieudonné Y, Bigot A, Terriou L, Vlakos A, de Maleprade B, Denis G, Broner J, Kostine M, Humbert S, Lifermann F, Samson M, Pechuzal S, Aouba A, Kosmider O, Dion J, Grosleron S, Bourguiba R, Terrier B, Georgin-Lavialle S, Fain O, Mekinian A, Morgand M, Comont T, Hadjadj J; French VEXAS Group. de Valence B, et al. Among authors: heiblig m. Ann Rheum Dis. 2024 Feb 15;83(3):372-381. doi: 10.1136/ard-2023-224819. Ann Rheum Dis. 2024. PMID: 38071510
VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P, Largeaud L, Jamilloux Y, Heiblig M, Kosmider O. Sujobert P, et al. Among authors: heiblig m. Expert Rev Hematol. 2023 Jul-Dec;16(7):495-499. doi: 10.1080/17474086.2023.2209715. Epub 2023 May 4. Expert Rev Hematol. 2023. PMID: 37119011
64 results